Trade Hikma Pharmaceuticals PLC - HIK CFD

Add to favourite

19.44

0.52%

0.10

Low: 19.23

High: 19.47

Market Trading Hours* (UTC) Open now
Closes on Monday at 12:00

Mon: 08:00 - 12:00 12:03 - 16:30

Tue: 08:00 - 12:00 12:03 - 12:30

Fri: 08:00 - 12:00 12:03 - 16:30

Summary
Historical Data

Trading сonditions

Spread

0.10

Long position overnight fee

-0.023925%

Short position overnight fee

0.002007%

Overnight fee time

22:00 (UTC)

Min traded quantity

Currency

GBP

Margin

5.00%

Stock exchange

United Kingdom of Great Britain and Northern Ireland

Commission on trade

Key Stats

Prev. Close	19.37
Open	19.23
1-Year Change	8.58%
Day's Range	19.23 - 19.47

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Dec 20, 2024	19.37	0.24	1.25%	19.13	19.53	19.07
Dec 19, 2024	19.26	0.22	1.16%	19.04	19.32	18.97
Dec 18, 2024	19.21	0.05	0.26%	19.16	19.28	18.86
Dec 17, 2024	18.88	-0.31	-1.62%	19.19	19.33	18.51
Dec 16, 2024	19.38	0.08	0.41%	19.30	19.41	19.00
Dec 13, 2024	19.23	-0.17	-0.88%	19.40	19.51	19.07
Dec 12, 2024	19.47	0.00	0.00%	19.47	19.70	19.39
Dec 11, 2024	19.56	0.17	0.88%	19.39	19.62	19.30
Dec 10, 2024	19.50	-0.28	-1.42%	19.78	19.79	19.38
Dec 9, 2024	19.20	-0.17	-0.88%	19.37	19.58	18.95
Dec 6, 2024	19.28	0.20	1.05%	19.08	19.43	19.07
Dec 5, 2024	19.38	-0.14	-0.72%	19.52	19.57	19.20
Dec 4, 2024	19.16	-0.31	-1.59%	19.47	19.64	19.16
Dec 3, 2024	19.12	-0.19	-0.98%	19.31	19.62	19.12
Dec 2, 2024	19.29	-0.05	-0.26%	19.34	19.40	19.08
Nov 29, 2024	18.98	-0.28	-1.45%	19.26	19.45	18.98
Nov 28, 2024	19.38	-0.20	-1.02%	19.58	19.66	19.33
Nov 27, 2024	19.50	-0.13	-0.66%	19.63	19.71	19.44
Nov 26, 2024	19.67	-0.07	-0.35%	19.74	19.83	19.48
Nov 25, 2024	19.72	0.24	1.23%	19.48	19.90	19.38

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

1:1
2:1
3:1
5:1
10:1
20:1

Leverage

20:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Hikma Company profile

Discover the latest Hikma share price today with our comprehensive live chart.

Hikma Pharmaceuticals plc. (HIK) creates and sells generic pharmaceutical solutions and products in the USA, North Africa, Europe, and the Middle East; with its headquarters located in London, UK. The company has operations in more than 50 countries and divides its work into three business units: Branded, Injectables, and Generics.

Hikma owns 29 manufacturing plants in 11 countries: Jordan, Saudi Arabia, Algeria, Egypt, Morocco, Tunisia, Sudan, United States, Portugal, Italy and Germany. The Hikma’s branded division offers 499 products in 1,256 dosage strength. The most popular products are: Amoclan, Omnisef, Blopress and Suprax. The injectables division vendors 200 products in 379 dosage forms.

Hikma pharmaceuticals share price is set and traded on the London Stock Exchange (LSE) under the ticker symbol HIK. The company constitutes the FTSE 100 and FTSE 350 Indices.

Hikma made an initial public offering on 11 November 2005, and Hikma pharmaceuticals shares were listed for the first time, raising gross proceeds of $124 million.

Hikma Pharmaceuticals was founded in Amman, Jordan, by Samih Darwazah in 1978. In August 1996, it became the first Arab company to export pharmaceutical products to the US.

The company’s biggest acquisitions include Jazeera Pharmaceutical, Saudi Arabia; Instituto Biochimico Pavese Pharma, Italy; Baxter International, US; Ribosepharm, Germany; Promopharm, Morocco, and Alkan Pharma, Egypt. All of these strategic acquisitions helped Hikma to establish itself as the world’s leading provider in its industry.

In May 2014, Hikma Pharmaceuticals plc significantly increased its presence in the injected medicine market by purchasing assets from the US generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300 million.

The most recent company acquisition was Roxane Laboratories in Columbus, US. It has majorly improved Hikma's position in a non-injectables business in the US market.

Hikma has been recognised as the Company of the Year by the Global Generics and Biosimilars Awards for four years in a row: from 2014 to 2017.

According to Hikma’s latest earnings report, the company delivered strong growth in revenue and profit in 2019 with a group core revenue of $2,203 million (up 6 per cent) and operating profit of $508 million (up 10 per cent).

Follow the Hikma share price today with Capital.com to spot the best trading opportunities. Track all the ups and downs of the HIK stock price and stay on top of the latest price fluctuations with our live Hikma stock chart.

Industry:

Pharmaceuticals (NEC)

1 New Burlington Place
LONDON
W1S 2HR
GB

News

Pi Network coin price prediction: Third party price target

Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com

13:51, 13 December 2024

Euro forecast: third party data roundup

In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.

22:39, 12 December 2024

Projected US interest rates in 5 years: Third party round up

As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?

14:28, 12 December 2024

Street in City of London with Royal Exchange, Bank of England and new modern skyscrapers

Projected UK interest rates in 5 years

Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?

11:20, 12 December 2024